| Mean (SD) | |
| Spherical equivalent | −12.9 (6.0) |
| Age | 48.9 (13.0) |
| Sex (female/male) | 22/14 |
| Choroidal neovascularisation diameter | 1507 (782) |
| Total photodynamic therapy sessions | 3.3 (1.5) |
| ETDRS lines baseline (n = 39) | 9.0 (4.3) |
| ETDRS lines 6 months (n = 38) | 10.2 (3.6) |
| ETDRS lines 12 months (n = 37) | 10.4 (3.6) |
| ETDRS lines 18 months (n = 37) | 10.0 (3.6) |
| ETDRS lines 24 months (n = 34) | 9.7 (3.9) |
| ETDRS lines 30 months (n = 33) | 10.5 (3.6) |
| ETDRS lines 36 months (n = 34) | 9.6 (3.8) |
| ETDRS lines 42 months (n = 33) | 9.7 (3.8) |
| ETDRS lines 48 months (n = 39) | 9.6 (4.2) |
| ETDRS lines gain (baseline-12) | p = 0.006 (Student t test for paired data) |
| ETDRS lines gain (baseline-24) | p = 0.30 (Student t test for paired data) |
| ETDRS lines gain (baseline-36) | p = 0.97 (Student t test for paired data) |
| ETDRS lines gain (baseline-48) | p = 0.38 (Student t test for paired data) |
- Original Article
- Clinical science
Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years’ outcome
Register for free content
Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of
BJO.
View free sample issue >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.









